|Treatment||N||Relapsed Brain Tumor||Medium # Recurrences||mOS (months)||Survival Rate (%)|
|6 months||9 months||12 months|
|Ad + V (Overall)||17||16 GBM, 1 AA||3||12.8||87||65||54|
|Ad + V (20 mg)||7||6 GBM, 1 AA||3||12.8||100||86||71|
Six of nine breast cancer patients treated with an experimental gene therapy from Ziopharm Oncology ZIOP experienced a potentially dangerous immune system-related toxicity known as cytokine release syndrome.
Ziopharm Oncology (ZIOP) reported stronger-than-expected results for the 2016 second quarter following Tuesday's closing bell.